Shares of drug developer Zura Bio (ZURA.O) rise 9.18% to $5.47 in early trading
Co appoints Sandeep Kulkarni, a director on Zura’s board, as CEO, replacing Robert Lisicki
Kulkarni earlier co-founded Tourmaline Bio, later bought by Novartis (NOVN.S)
Outgoing CEO Lisicki had proceeded on medical leave in October, with Kim Davis taking on the role in the interim
Co’s lead drug tibulizumab is in mid-stage tests for hidradenitis suppurativa and systemic sclerosis, both long-lasting autoimmune conditions, per co
Co says key trial readouts expected within 18 months
Shares up ~110% in 2025

IBBQ

SBIO

ZURA

Shares of drug developer Zura Biorise 9.18% to $5.47 in early tradingCo appoints Sandeep Kulkarni, a director on Zura’s board, as CEO, replacing Robert LisickiKulkarni earlier co-founded Tourmaline Bio, later bought by Novartis (NOVN.S) Outgoing CEO Lisicki had proceeded on medical leave in October, with Kim Davis taking on the role in the interimCo’s lead drug tibulizumab is in mid-stage tests for hidradenitis suppurativa and systemic sclerosis, both long-lasting autoimmune conditions, per coCo says key trial readouts expected within 18 monthsShares up ~110% in 2025

Reuters

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

iShares Biotechnology ETF

Zura Bio

VanEck Biotech ETF

SPDR S&P Biotech

BUZZ-Zura Bio names new CEO; shares rise